William B Nicolson1, Gerry P McCann1, Matthew I Smith2, Alastair J Sandilands3, Peter J Stafford3, Fernando S Schlindwein4, Nilesh J Samani1, G André Ng1. 1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK University Hospitals of Leicester NHS Trust, Leicester, UK. 2. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. 3. University Hospitals of Leicester NHS Trust, Leicester, UK. 4. NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK Department of Engineering, University of Leicester, Leicester, UK.
Abstract
OBJECTIVE: To improve prediction of sudden cardiac death (SCD) in patients with ischaemic cardiomyopathy (ICM). Electrical heterogeneity is known to contribute to risk of SCD. We have previously developed Regional Restitution Instability Index (R2I2), an ECG-based biomarker, which quantifies cardiac electrical instability by measuring heterogeneity in electrical restitution, and demonstrated its potential utility for risk stratification in a retrospective analysis of patients with ICM. Here, we examined R2I2 in a prospective ICM cohort and also tested the predictive value of another ECG-based biomarker, Peak ECG Restitution Slope (PERS). METHODS: Prospective, blinded, observational study of 60 patients with ICM undergoing implantable cardioverter defibrillator risk stratification. R2I2 was calculated from an electrophysiological study (EPS) using ECG surrogates for action potential duration and diastolic interval. R2I2 quantifies inter-lead electrical restitution heterogeneity. PERS was the peak restitution curve slope taken as a mean across the 12 ECG leads. Endpoints were ventricular arrhythmia (VA)/SCD. RESULTS: Over median follow-up of 22 months, 16 (26.6%) patients achieved endpoint. R2I2 was significantly higher in these patients compared with those without an event (mean ± SEM: 1.11 ± 0.09 vs 0.84 ± 0.04, p=0.003) as was PERS (median(IQR): 1.35(0.60) vs 1.08(0.52), p=0.014). R2I2≥1.03, the cut-off used in our previous study, identified patients with a significantly higher risk of VA/SCD independent of EPS result, LVEF or QRS duration with a relative risk of 6.5 (p=0.008). Patients positive for R2I2 and PERS had a relative risk of VA/SCD 21.6 times that of those negative for R2I2 and PERS (p<0.0001). CONCLUSIONS: R2I2 and PERS each independently and in combination, identify patients with ICM that are at high risk of developing ventricular arrhythmias (VA). R2I2/PERS represent promising risk markers for SCD discrimination. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT01944514. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To improve prediction of sudden cardiac death (SCD) in patients with ischaemic cardiomyopathy (ICM). Electrical heterogeneity is known to contribute to risk of SCD. We have previously developed Regional Restitution Instability Index (R2I2), an ECG-based biomarker, which quantifies cardiac electrical instability by measuring heterogeneity in electrical restitution, and demonstrated its potential utility for risk stratification in a retrospective analysis of patients with ICM. Here, we examined R2I2 in a prospective ICM cohort and also tested the predictive value of another ECG-based biomarker, Peak ECG Restitution Slope (PERS). METHODS: Prospective, blinded, observational study of 60 patients with ICM undergoing implantable cardioverter defibrillator risk stratification. R2I2 was calculated from an electrophysiological study (EPS) using ECG surrogates for action potential duration and diastolic interval. R2I2 quantifies inter-lead electrical restitution heterogeneity. PERS was the peak restitution curve slope taken as a mean across the 12 ECG leads. Endpoints were ventricular arrhythmia (VA)/SCD. RESULTS: Over median follow-up of 22 months, 16 (26.6%) patients achieved endpoint. R2I2 was significantly higher in these patients compared with those without an event (mean ± SEM: 1.11 ± 0.09 vs 0.84 ± 0.04, p=0.003) as was PERS (median(IQR): 1.35(0.60) vs 1.08(0.52), p=0.014). R2I2≥1.03, the cut-off used in our previous study, identified patients with a significantly higher risk of VA/SCD independent of EPS result, LVEF or QRS duration with a relative risk of 6.5 (p=0.008). Patients positive for R2I2 and PERS had a relative risk of VA/SCD 21.6 times that of those negative for R2I2 and PERS (p<0.0001). CONCLUSIONS: R2I2 and PERS each independently and in combination, identify patients with ICM that are at high risk of developing ventricular arrhythmias (VA). R2I2/PERS represent promising risk markers for SCD discrimination. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT01944514. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Julia Ramírez; Michele Orini; Ana Mincholé; Violeta Monasterio; Iwona Cygankiewicz; Antonio Bayés de Luna; Juan Pablo Martínez; Esther Pueyo; Pablo Laguna Journal: J Am Heart Assoc Date: 2017-05-19 Impact factor: 5.501
Authors: Gary Tse; Mengqi Gong; Lei Meng; Cheuk W Wong; George Bazoukis; Matthew T V Chan; Martin C S Wong; Konstantinos P Letsas; Adrian Baranchuk; Gan-Xin Yan; Tong Liu; William K K Wu Journal: Front Physiol Date: 2018-09-03 Impact factor: 4.566
Authors: Michael J Shattock; Kyung Chan Park; Hsiang-Yu Yang; Angela W C Lee; Steven Niederer; Kenneth T MacLeod; James Winter Journal: Cardiovasc Res Date: 2017-06-01 Impact factor: 10.787
Authors: Konstantinos N Aronis; Adityo Prakosa; Teya Bergamaschi; Ronald D Berger; Patrick M Boyle; Jonathan Chrispin; Suyeon Ju; Joseph E Marine; Sunil Sinha; Harikrishna Tandri; Hiroshi Ashikaga; Natalia A Trayanova Journal: Front Physiol Date: 2021-07-14 Impact factor: 4.566